Announcement PDF Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Recce Pharmaceuticals Ltd (Company) ACN 124 849 065 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Michele Keryn Dilizia Date of last notice 16 February 2016 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Interest Nature of indirect interest (including registered holder) N/A Date of change 2 August 2019 5 August 2019 6 August 2019 7 August 2019 No. of securities held prior to change 2,886,061 fully paid ordinary shares Note: Provide details of the circumstances giving rise to the relevant interest. 577,212 Class B Performance Shares (and any fully paid ordinary shares issued on conversion) 577,212 Class C Performance Shares (and any fully paid ordinary shares issued on conversion) 577,212 Class D Performance Shares (and any fully paid ordinary shares issued on conversion) Class + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Fully paid ordinary shares Appendix 3Y Change of Director’s Interest Notice Number acquired Nil Number disposed 277,000 fully paid ordinary shares Value/Consideration $60,180 No. of securities held after change 2,609,061 fully paid ordinary shares Note: If consideration is non-cash, provide details and estimated valuation 577,212 Class B Performance Shares (and any fully paid ordinary shares issued on conversion) 577,212 Class C Performance Shares (and any fully paid ordinary shares issued on conversion) 577,212 Class D Performance Shares (and any fully paid ordinary shares issued on conversion) Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back On-market sale of 277,000 fully paid ordinary shares Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change N/A Interest acquired N/A Interest disposed N/A Value/Consideration N/A Interest after change N/A Note: Details are only required for a contract in relation to which the interest has changed Note: If consideration is non-cash, provide details and an estimated valuation + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? No If prior written clearance was provided, on what date was this provided? N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 N/A